--- title: Effect of Fasting on the NLRP3 Inflammasome nct_id: NCT02122575 overall_status: COMPLETED sponsor: National Heart, Lung, and Blood Institute (NHLBI) study_type: OBSERVATIONAL primary_condition: Cardiovascular Disease countries: United States canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02122575.md" clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02122575" ct_last_update_post_date: 2021-02-01 last_seen_at: "2026-05-12T07:14:25.713Z" source: ClinicalTrials.gov (mirrored, no enrichment) --- # Effect of Fasting on the NLRP3 Inflammasome **Official Title:** Pilot Study to Evaluate the Effect of Fasting on the NLRP3 Inflammasome **NCT ID:** [NCT02122575](https://clinicaltrials.gov/study/NCT02122575) ## Key Facts - **Status:** COMPLETED - **Study Type:** OBSERVATIONAL - **Target Enrollment:** 23 - **Lead Sponsor:** National Heart, Lung, and Blood Institute (NHLBI) - **Conditions:** Cardiovascular Disease, Inflammatory Disease - **Start Date:** 2014-04-21 - **Completion Date:** 2021-01-27 - **CT.gov Last Update:** 2021-02-01 ## Brief Summary Background: \- Restricting calories can help a person reduce risk factors for heart disease. Researchers have found that not eating or drinking anything but water for 24 hours prevents the activation of a component of the immune system, called the inflammasome. The inflammasome is associated with the development of diabetes and heart disease. Researchers want to learn more about the body s response to fasting. Objective: \- To explore the benefits of calorie restriction on heart health. Eligibility: \- Healthy adults ages 21 32 with a body mass index between 26 and 29. Design: * Participants will be screened with a medical history, physical exam and blood test. * Participants will not eat or drink after 10 p.m. before their first visit. * Participants have breakfast at the clinic. The breakfast will be about 500 calories. Then they will not eat or drink (except water) for 24 hours. * Participants will return to the clinic the next morning. They will have blood drawn. Then they will have breakfast. Blood will be drawn again at 1 hour and 3 hours after the meal. * Blood and urine tests at the end of the fast and following the meals will be done to confirm that participants have fasted for the full 24-hour period. ## Detailed Description A caloric restricted diet has numerous health effects including the reduction in numerous cardiovascular disease risk factors. The cellular programs activated by caloric restriction are similarly turned on in preclinical studies in response to a 24-hour fast. We have found that a beneficial effect of a 24-hour fasting blunts the activation of a component of the immune system, termed the inflammasome, which is associated with the development of diabetes and atherosclerosis. We would like to study the inflammasome in human blood cells to evaluate whether the beneficial immune effects of fasting/caloric restriction are operational in humans. Blood samples to test the immune response will be collected in subjects after a fixed caloric meal and in response to a 24-hour fast (water intake will not be restricted). The objective of this pilot study is to identify if these immune adaptive pathways can be activated in human subjects as a possible readout to test whether this pathway could be investigated as a therapeutic target to blunt/negate the inflammation associated with nutrient-excess associated diseases such as diabetes and/or atherosclerosis. ## Eligibility - **Minimum age:** 21 Years - **Maximum age:** 37 Years - **Sex:** ALL - **Healthy Volunteers:** No ``` * INCLUSION CRITERIA: As this is a pilot study, the age-range and BMI range of subjects will be restricted to potentially reduce metabolic variables associated with a wide age- and BMI-range. * Males and females between the ages of 21 and 37 * BMI between 23.5 and 29 EXCLUSION CRITERIA: * Subjects with an acute or chronic illness as per history, on laboratory analysis or due to use of medications * Subjects taking vitamins or supplements or any medications, except oral contraceptives within 4 weeks of participation into this study. * BMI \<23.5 or \>29 * Female subjects who are pregnant or lactating * Subjects who have donated blood or participated in another clinical trial involving blood draws in the last 8 weeks. * Subjects who use nicotine products ``` ## Arms - **1** — Males and females between the ages of 21 and 37 ## Primary Outcomes - **Determine whether the NLRP3 inflammasome is blunted by a 24 hours fast in PBMC's from normal volunteers.** _(time frame: 24 hours)_ — The primary outcome will be the change in IL-1 secretion in response to inflammasome stimulation in PBMC s comparing the fasted response to the fed response. As there are two fed responses, we will initially determine whether inflammasome induction differs between the peak post- prandial insulin effect (1 hr) and the peak post-prandial fatty acid levels (3 hr). The higher mean IL-1 levels between the two fed states will be considered the index fed response and will be compared to the fasting levels as the primary outcome. The comparisons will be performed using paired two-tailed Student t-tests. Significance will be tested at the 0.05 alpha level in this pilot study. ## Secondary Outcomes - **Evaluate whether these effects are associated with activation of the Sirt3 and its canonical mitochondrial adaptive programs.** _(time frame: end of study)_ - **Determine whether serum from subjects in fasted state will blunt the inflammasome compared to serum from the fed stat in a human transformed macrophage cell line.** _(time frame: end of study)_ ## Locations (1) - National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States ## Recent Field Changes (last 30 days) - `status.overallStatus` — added _(2026-05-12)_ - `status.primaryCompletionDate` — added _(2026-05-12)_ - `status.completionDate` — added _(2026-05-12)_ - `status.lastUpdatePostDate` — added _(2026-05-12)_ - `design.enrollmentCount` — added _(2026-05-12)_ - `eligibility.criteria` — added _(2026-05-12)_ - `eligibility.minAge` — added _(2026-05-12)_ - `eligibility.maxAge` — added _(2026-05-12)_ - `eligibility.sex` — added _(2026-05-12)_ - `outcomes.primary` — added _(2026-05-12)_ - `outcomes.secondary` — added _(2026-05-12)_ - `armsInterventions.arms` — added _(2026-05-12)_ - `sponsor.lead` — added _(2026-05-12)_ - `results.hasResults` — added _(2026-05-12)_ - `locations.national institutes of health clinical center, 9000 rockville pike|bethesda|maryland|united states` — added _(2026-05-12)_ --- *Canonical: https://parkinsonspathways.com/agent/trials/NCT02122575.md* *Source data (authoritative): https://clinicaltrials.gov/study/NCT02122575* *This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*